Axa Sells 102989 Shares of Alexion Pharmaceuticals, Inc. (ALXN)

Lawrence Kim
December 15, 2017

The biopharmaceutical company reported $1.44 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $1.32 by $0.12. Baker Bros Advisors Lp who had been investing in Alexion Pharmaceuticals Inc. for a number of months, seems to be bullish on the $25.37B market cap company. The stock increased 0.70% or $0.36 during the last trading session, reaching $52.01. About 2.82M shares traded or 13.82% up from the average. (NASDAQ:ALXN) news were published by: Businesswire.com which released: "Myasthenia Gravis Therapeutics Pipeline Analysis 2017 - Key Players are ..." on December 13, 2017, also Seekingalpha.com with their article: "Alexion +2.6% on report Elliott has taken activist stake" published on December 08, 2017, Prnewswire.com published: "Quotidian Technical Highlights on Selected Biotech Stocks - Amgen, Alexion ..." on December 14, 2017. According to the most recent data, Alexion Pharmaceuticals, Inc. has a 52-week high of $149.34 and a 52-week low of $96.18. Neuberger Berman Grp Lc accumulated 272,363 shares or 0.04% of the stock. Hedge funds and other institutional investors own 94.33% of the company's stock. Volume in the last session has decreased compared with ALXN's average trading volume. It has underperformed by 34.82% the S&P500.

Since December 11, 2017, it had 0 insider purchases, and 1 insider sale for $51,700 activity. Therefore 71% are positive. The firm has "Neutral" rating given on Friday, September 8 by Janney Capital. Keefe Bruyette & Woods maintained the stock with "Buy" rating in Monday, May 29 report. The stock has "Buy" rating by Vetr on Wednesday, August 12. The rating was maintained by Barclays Capital with "Equal-Weight" on Thursday, February 4. The firm earned "Buy" rating on Thursday, February 4 by UBS. "(NASDAQ:ALXN)" was originally posted by TrueBlueTribune and is the property of of TrueBlueTribune.

Investors sentiment is 1.16 in 2017 Q2. Its the same as in 2017Q1. Ahl Llp invested in 17,971 shares. Wetherby Asset, a California-based fund reported 10,801 shares. About 1.54M shares traded or 19.67% up from the average. Ferguson Wellman Capital Incorporated reported 21,545 shares. Hanson And Doremus Investment Management holds 540 shares. Stephens Ar has 6,683 shares for 0.03% of their portfolio. Alexion Pharmaceuticals, Inc. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.51 and a current ratio of 2.96. Walleye Trading owns 0% invested in Amarin Corporation plc (NASDAQ:AMRN) for 1,000 shares. (NYSE:HIW) for 178,122 shares.

Timber Hill Llc, which manages about $2.65B US Long portfolio, decreased its stake in Firstenergy Corp (Put) by 18,400 shares to 14,100 shares, valued at $411,000 in 2017Q2, according to the filing. It also reduced its holding in Westrock Co (Call) by 8,900 shares in the quarter, leaving it with 15,600 shares, and cut its stake in Microsoft Corp (Call).

Christopher Coughlin has seen steady activity on the buy side, and on December 5, 2017, executed an option to buy 10000 shares.

Axa reduced its position in shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) on Tuesday, September 5 to "Buy" rating. The Price to Cash Flow for Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), 22 have Buy rating, 0 Sell and 6 Hold. Therefore 79% are positive. The firm has "Overweight" rating by JP Morgan given on Monday, July 27. RBC Capital Markets has "Outperform" rating and $177 target. As per Friday, September 23, the company rating was initiated by Wedbush. The rating was maintained by Stifel Nicolaus on Friday, July 29 with "Buy". The rating was maintained by Stifel Nicolaus on Friday, June 23 with "Buy".

Oppenheimer upgraded Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) advice adding it to buy candidate list. (NASDAQ:ALXN) rating on Friday, July 31. Its down 0.20, from 1.37 in 2017Q1. (ALXN) worth $725.94 million at the end of the most recent reporting period.The investor is now holding 6,390,301 shares thanks to an increase of 215,005 new shares in their portfolio. 72 funds opened positions while 203 raised stakes.

As it reflects the theoretical cost of buying the company's shares, the market cap of Alexion Pharmaceuticals, Inc. Honeywell Intll accumulated 189,300 shares. (NASDAQ:ALXN). Numeric reported 0.01% of its portfolio in Alexion Pharmaceuticals, Inc. Sterling Ltd Limited Liability Company owns 46,335 shares or 0% of their United States portfolio. Jane Street Group Incorporated Ltd Company holds 0.02% of its portfolio in Alexion Pharmaceuticals, Inc.

Several research analysts have recently weighed in on ALXN shares. Barings LLC lifted its position in Alexion Pharmaceuticals by 92.8% during the third quarter. (NASDAQ:ALXN). Gateway Invest Advisers Lc holds 0.17% or 154,531 shares in its portfolio.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, October 26th. Blackrock owns 19.93 million shares for 0.13% of their portfolio. (NASDAQ:ALXN) latest ratings and price target changes. Thornburg Invest Mngmt invested in 101,610 shares. Ameritas Inv Partners, a Nebraska-based fund reported 9,283 shares. (NasdaqGS:ALXN) is 0.037623. Earnings Yield helps investors measure the return on investment for a given company. Credit Agricole S A holds 0.03% or 83,317 shares.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Other reports by Click Lancashire

Discuss This Article

FOLLOW OUR NEWSPAPER